<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108860</url>
  </required_header>
  <id_info>
    <org_study_id>ABROGATE 5527</org_study_id>
    <secondary_id>2013-005535-24</secondary_id>
    <secondary_id>5527</secondary_id>
    <nct_id>NCT02108860</nct_id>
  </id_info>
  <brief_title>Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)</brief_title>
  <official_title>Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of
      abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing
      non-severe granulomatosis with polyangiitis (Wegener's) (GPA) . Participants will be
      randomized 1:1 to receive either abatacept 125 mg or placebo administered by subcutaneous
      injection once a week. Participants will continue on study treatment for a minimum of 12
      months unless they experience a disease relapse or disease flare.

      Participants who experience a non-severe disease relapse, non-severe disease worsening, or
      who have not achieved remission by month 6 will have the option of entering an open-label
      trial period whereby they would receive open-label abatacept.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of
      abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing
      non-severe GPA. Patients who enter the trial will be maintained on a stable dose of their
      maintenance immunosuppressive agent which may include methotrexate (MTX), azathioprine (AZA),
      or mycophenolate (MA) and will undergo a blinded randomization to receive abatacept or
      placebo. Patients will additionally receive prednisone 30 mg daily that will then be tapered
      to zero using a standardized tapering schedule.

      If an enrolled patient experiences a non-severe relapse or non-severe disease worsening
      though common closing, or if they have not achieved remission by month 6, they will have the
      option of entering an open-label trial period whereby they would receive abatacept in
      conjunction with their maintenance immunosuppressive and a standardized glucocorticoid taper.
      Patients with a severe disease relapse or severe disease worsening will have met criteria for
      early termination criteria and be removed from active study treatment. Patients will remain
      on study until reaching criteria for early termination or until common closing, 12 months
      after randomization of the final patient. After common closing or early termination, patients
      will be treated with best medical judgment and will undergo a post-treatment safety visit 3
      months after coming off of study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure after 12 months of study treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment failure will be defined as relapse, disease worsening, or failure to achieve a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) = 0 or 1 by 6 months.
Relapse will be defined as any of the following after remission: an increase in BVAS/WG, development of a new BVAS/WG item, or symptoms/signs of GPA that cannot be attributed to any cause other than GPA and that requires institution or dosage increase of prednisone.
Disease worsening will be defined as any of the following prior to remission: an increase in BVAS/WG, development of a new BVAS/WG item, or symptoms/signs of GPA that cannot be attributed to any cause other than GPA and that requires institution or dosage increase of prednisone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of glucocorticoid-free periods</measure>
    <time_frame>12 months</time_frame>
    <description>Effect of abatacept on increasing duration of glucocorticoid-free periods for participants. Patients will be treated with abatacept for a minium of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission with abatacept versus placebo</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of GPA disease remission on participants on abatacept versus placebo. Patients will be treated with abatacept for a minium of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of relapses in those treated with abatacept versus placebo</measure>
    <time_frame>12 months</time_frame>
    <description>Severity of GPA disease relapses in those treated with abatacept versus placebo. Patients will be treated with abatacept for a minium of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life in those treated with abatacept versus placebo</measure>
    <time_frame>12 months</time_frame>
    <description>Health-related quality of life in those treated with abatacept versus placebo as assessed using the SF-36 and PROMIS questionnaires. Patients will be treated with abatacept for a minium of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety of abatacept in patients with GPA as assessed by reported adverse events. Patients will be treated with abatacept for a minium of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Granulomatosis With Polyangiitis (Wegener's)</condition>
  <condition>Granulomatosis With Polyangiitis</condition>
  <condition>Wegener's Granulomatosis</condition>
  <condition>ANCA-Associated Vasculitis</condition>
  <arm_group>
    <arm_group_label>Blinded abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blinded placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .</description>
    <arm_group_label>Blinded abatacept</arm_group_label>
    <other_name>CTLA4-Ig</other_name>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.</description>
    <arm_group_label>blinded placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be considered as being best characterized as GPA and not microscopic
             polyangiitis (MPA) or eosinophilic granulomatosis with polyangiitis (EGPA) and must
             have met at least 2 of the 5 modified ACR classification criteria for GPA. These do
             not need to be present at the time of study entry. The modified ACR criteria are:

               1. Nasal or oral inflammation, defined as the development of painful or painless
                  oral ulcers or purulent or bloody nasal discharge

               2. Abnormal chest radiograph, defined as the presence of nodules, fixed infiltrates,
                  or cavities

               3. Active urinary sediment, defined as microscopic hematuria (&gt;5 red blood cells per
                  high power field) or red blood cell casts

               4. Granulomatous inflammation on biopsy, defined as histologic changes showing
                  granulomatous inflammation within the wall of an artery or in the perivascular or
                  extravascular area (artery or arteriole)

               5. Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for
                  proteinase-3 or myeloperoxidase measured by enzyme-linked immunoassay

          2. Relapse of GPA within the 28 days prior to screening where the active disease features
             meet the following definition of non-severe disease:

               1. No disease manifestations that would be scored as a major element in the BVAS/WG

               2. Absence of any disease feature that poses an immediate threat to either a
                  critical individual organ or the patient's life

          3. Age 15 and older

          4. Willing and able to comply with treatment and follow-up procedures

          5. Both women and men must be willing to use an effective means of birth control while
             receiving treatment through this study. Women should continue the use of an effective
             means of birth control for a minimum of 14 weeks after the last dose of study drug.
             Effective contraception methods include abstinence, oral contraceptives (birth control
             pills), IUD, diaphragm, Norplant, approved hormone injections, condoms, or medical
             sterilization.

          6. Willing and able to provide written informed consent (and written assent of minor
             participants if applicable.)

        Exclusion Criteria:

          1. Presence of involvement that does not meet the criteria for non-severe disease

          2. Treatment with CYC within 3 months prior to screening

          3. Treatment with methylprednisolone 1000 mg within 28 days prior to enrollment

          4. Treatment with prednisone &gt; 30 mg/day for &gt; 28 days immediately prior to study entry

          5. Initiation or dose increase of the maintenance immunosuppressive agent (MTX, AZA, MA)
             within 3 months prior to screening

          6. Evidence of active infection (includes chronic infection)

          7. Patients who are pregnant or who are nursing

          8. Known infection with human immunodeficiency virus (HIV), hepatitis C, or a positive
             hepatitis B surface antigen

          9. Inability to comply with study guidelines

         10. Cytopenia: platelet count &lt; 100,000/mm3, white blood cell count (WBC) &lt; 3,000/mm3 (3 x
             109/L), absolute neutrophil count &lt; 1500/mm3, hemoglobin (Hgb) &lt; 8.5 g/dL

         11. Chronic renal insufficiency defined by a creatinine clearance of &lt; or = to 20 ml/min

         12. Known current use of illegal drugs

         13. Other uncontrolled disease (co-morbidity) that could prevent a patient from fulfilling
             the study requirements or that would substantially increase the risk of study
             procedures

         14. History of malignancy within the past five years or any evidence of persistent
             malignancy, except fully excised basal cell or squamous cell carcinomas of the skin,
             or cervical carcinoma in situ which has been treated or excised in a curative
             procedure

         15. Receipt of an investigational agent or device within 30 days prior to enrollment or 5
             half lives of the investigational drug (whichever is longer)

         16. A live vaccination fewer than 3 months before enrollment

         17. Current clinical, radiographic, or laboratory evidence of active tuberculosis

         18. A history of active tuberculosis within the past 3 years even if treated

         19. A history of active tuberculosis greater than 3 years ago unless there is
             documentation of prior anti-tuberculosis treatment of appropriate duration and type

         20. Latent tuberculosis unless there is documentation of prior anti-tuberculosis treatment
             of appropriate duration and type

         21. Latent tuberculosis currently being treated with isoniazid (INH) or other therapy for
             latent tuberculosis given according to local health authority guidelines (e.g., Center
             for Disease Control (CDC)) who have received such therapy for 4 weeks or less prior to
             randomization (Day 1). Subjects with a positive tuberculosis screening test indicative
             of latent tuberculosis will be eligible for the study if they have no evidence of
             current tuberculosis on chest xray at screening and they are actively being treated
             for tuberculosis with INH or other therapy for latent tuberculosis given according to
             local health authority guidelines (e.g., CDC) that has been given for at least 4 weeks
             prior to randomization (Day 1). These subjects must complete treatment according to
             local health authority guidelines.

         22. History of herpes zoster that resolved less than 2 months prior to enrollment

         23. Treatment with rituximab or any other biologic B cell depleting agent within the past
             6 months or past treatment with rituximab or any other biologic B cell depleting agent
             where the B lymphocyte count remains &lt; 60 cells/uL

         24. Treatment with alemtuzumab or anti-thymocyte globulin within the last 12 months

         25. Treatment with intravenous immunoglobulin or plasma exchange within the past 3 months

         26. Treatment with infliximab, etanercept, adalimumab, tocilizumab, or any other biologic
             agent within the past 3 months or 5 half lives of the agent (whichever is longer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol A Langford, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey P Krischer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter A Merkel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Burroughs</last_name>
    <phone>1-888-772-8315</phone>
    <email>abrogate@epi.usf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahbuba Tusty</last_name>
      <phone>310-423-3032</phone>
      <email>mahbuba.tusty@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Michael H Weisman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsy Forbess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Goglin</last_name>
      <email>sarah.goglin@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Goglin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida Rheumatology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Orzechowski</last_name>
      <phone>813-974-2473</phone>
      <email>mpatelli@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Yih Chang Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin McMillian</last_name>
      <phone>913-588-0681</phone>
      <email>cmcmillian@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Springer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Amudala, NP</last_name>
      <phone>617-414-2512</phone>
      <email>namudala@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Monach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Lewis</last_name>
      <phone>734-936-4009</phone>
      <email>eelewis@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ora Gewurz-Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boleyn Andrist</last_name>
      <phone>800-743-1606</phone>
      <email>Andrist.boleyn@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sue Ann Donlinger</last_name>
      <phone>507-284-9259</phone>
      <email>Donlinger.SueAnn@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Specks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Ytterberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annel Fernandez</last_name>
      <phone>212-774-2123</phone>
      <email>fernandeza@hss.edu</email>
    </contact>
    <investigator>
      <last_name>Robert F Spiera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsay Lally, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol A Langford, MD, MHS</last_name>
      <phone>216-445-6056</phone>
      <email>langfoc@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Sonya Crook</last_name>
      <phone>216-444-3290</phone>
      <email>crooks@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carol A Langford, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cailin Sibley, MD, MHS</last_name>
      <phone>503-494-6115</phone>
      <email>sibleyc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Cailin Sibley, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roni Devassy</last_name>
      <phone>215-614-4407</phone>
      <email>Roni.Devassy@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter A Merkel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine Sreih, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Hope</last_name>
      <phone>412-647-2638</phone>
      <email>hopelk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Moreland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meena Golchha</last_name>
      <phone>615-875-8356</phone>
      <email>meenakshi.golchha@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Narender Annapureddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gonzalez</last_name>
      <phone>801-585-0797</phone>
      <email>jessica.gonzalez@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Curry Koening, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore Fifi-Mah, MD</last_name>
      <phone>403-210-7113</phone>
      <email>avfifima@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Aurore Fifi-Mah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Health Services- Edmonton</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanne Stewart</last_name>
      <phone>780-407-6179</phone>
      <email>Breanne.Stewart@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Elaine Yacyshyn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, St. Paul's Rheumatology Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marx Jayaraman</last_name>
      <phone>604-682-2344</phone>
      <phone_ext>63566</phone_ext>
      <email>JJayaraman@cheos.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Kam Shojania, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natasha Dehghan, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital, Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Messier</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35873</phone_ext>
      <email>smessier@stjoes.ca</email>
    </contact>
    <investigator>
      <last_name>Nader Khalidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>k1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Patterson</last_name>
      <phone>613-738-8400</phone>
      <phone_ext>81630</phone_ext>
      <email>ppatterson@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Nataliya Milman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital, Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Weber</last_name>
      <phone>416-586-8616</phone>
      <email>advanced@sinaithealthsystem.ca</email>
    </contact>
    <investigator>
      <last_name>Simon Carette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Pagnoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Gallagher</last_name>
      <phone>0035312214773</phone>
      <email>P.Gallagher@st-vincents.ie</email>
    </contact>
    <investigator>
      <last_name>Eamonn Molloy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Aberdeen</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Hutcheon</last_name>
      <email>gayle.hutcheon@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Neil Basu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dana Kidder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cambridge- Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Dahlsveen</last_name>
      <phone>01223 349530</phone>
      <email>karen.dahlsveen@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Jayne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark McClure, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rarediseasesnetwork.org/cms/vcrc/Research/Studies/5527</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulomatosis with polyangiitis (Wegener's)</keyword>
  <keyword>Granulomatosis with polyangiitis</keyword>
  <keyword>GPA</keyword>
  <keyword>Wegener's granulomatosis</keyword>
  <keyword>Wegener granulomatosis</keyword>
  <keyword>Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis</keyword>
  <keyword>ANCA Associated Vasculitis</keyword>
  <keyword>AAV</keyword>
  <keyword>Vasculitis</keyword>
  <keyword>Systemic vasculitis</keyword>
  <keyword>Systemic inflammatory disease</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Abatacept</keyword>
  <keyword>CTLA4-Ig</keyword>
  <keyword>Immunosuppressive agent</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Glucocorticoid</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Treatment</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Anti Inflammatory Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

